lifestyle.gamezon.net

Author: Aytu BioPharma, Inc.

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

May 6, 2026
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

February 3, 2026
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

January 27, 2026
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA

January 24, 2026
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

January 14, 2026
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

January 13, 2026
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

December 19, 2025
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

December 19, 2025